Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema.

Next Previous
Trial Profile

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary) ; Triamcinolone (Primary)
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms LRT for DME; PROTOCOL J

Most Recent Events

  • 07 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Dec 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
  • 09 Dec 2011 Primary endpoint identified (optical coherence tomography outcomes) as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top